Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Annamycin liposomal - Moleculin Biotech

Next Previous
X
Search
Drug Profile

Annamycin liposomal - Moleculin Biotech

Alternative Names: Annamycin-LF; Annamycin-liposomal; L-ANNA; L-annamycin; Liposomal annamycin; S-ANNA

Latest Information Update: 22 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Aronex Pharmaceuticals; Callisto Pharmaceuticals; Moleculin Biotech; University of Texas M. D. Anderson Cancer Center
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma; Precursor cell lymphoblastic leukaemia-lymphoma; Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase II Soft tissue sarcoma
  • Phase I/II Acute myeloid leukaemia
  • Preclinical Colorectal cancer; Liver cancer; Pancreatic cancer; Solid tumours
  • Discontinued Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Triple negative breast cancer

Most Recent Events

  • 14 Aug 2024 Updated efficacy and adverse events data from a phase I/II trial in Acute myeloid leukaemia released by Moleculin Biotech
  • 05 Aug 2024 Moleculin Biotech plans a phase III MIRACLE trial for Acute myeloid leukaemia (Second-line therapy or greater, combination therapy) worldwide in Q1 2025
  • 01 Aug 2024 Moleculin Biotech intends to amend current investigational new drug application

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top